Metformin modulates antioxidant and anti-inflammatory biomarkers in newly diagnosed patients with type 2 diabetes mellitus: an observational study.

Q3 Pharmacology, Toxicology and Pharmaceutics

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2026-01-22 eCollection Date: 2026-05-01 DOI:10.1515/jbcpp-2025-0201

Saurav Misra, Tirthankar Deb, Savita Devi, Amandeep Singh, Richa Goel

{"title":"Metformin modulates antioxidant and anti-inflammatory biomarkers in newly diagnosed patients with type 2 diabetes mellitus: an observational study.","authors":"Saurav Misra, Tirthankar Deb, Savita Devi, Amandeep Singh, Richa Goel","doi":"10.1515/jbcpp-2025-0201","DOIUrl":null,"url":null,"abstract":"Objectives: Diabetes mellitus is a chronic metabolic condition marked by high blood sugar levels. As a primary treatment for type 2 diabetes (T2DM), metformin has demonstrated positive effects on antioxidant and anti-inflammatory biomarkers in newly diagnosed patients.Methods: This was a prospective observational study. Blood samples were collected three times to analyse biomarkers. The study involved newly diagnosed T2DM patients who provided written informed consent. The assessments included plasma lipid peroxidation, superoxide dismutase (SOD), catalase, and Malondialdehyde (MDA) levels. Additionally, interleukin-6 (IL-6) was measured to evaluate inflammation.Results: HbA1c levels significantly decreased at the 6-month follow-up. Analysis showed a reduction in SOD levels at each visit, with a statistically significant difference between the first and second follow-ups (p=0.03028). MDA levels also decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05). Catalase levels increased at each visit, but only between the first and second follow-ups (p=0.03124). IL-6 levels decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05).Conclusions: Metformin reduces oxidative stress and inflammation in patients with type 2 diabetes, aiding in protecting cells and tissues.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"213-222"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Physiology and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jbcpp-2025-0201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Diabetes mellitus is a chronic metabolic condition marked by high blood sugar levels. As a primary treatment for type 2 diabetes (T2DM), metformin has demonstrated positive effects on antioxidant and anti-inflammatory biomarkers in newly diagnosed patients.

Methods: This was a prospective observational study. Blood samples were collected three times to analyse biomarkers. The study involved newly diagnosed T2DM patients who provided written informed consent. The assessments included plasma lipid peroxidation, superoxide dismutase (SOD), catalase, and Malondialdehyde (MDA) levels. Additionally, interleukin-6 (IL-6) was measured to evaluate inflammation.

Results: HbA1c levels significantly decreased at the 6-month follow-up. Analysis showed a reduction in SOD levels at each visit, with a statistically significant difference between the first and second follow-ups (p=0.03028). MDA levels also decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05). Catalase levels increased at each visit, but only between the first and second follow-ups (p=0.03124). IL-6 levels decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05).

Conclusions: Metformin reduces oxidative stress and inflammation in patients with type 2 diabetes, aiding in protecting cells and tissues.

查看原文本刊更多论文

二甲双胍调节新诊断的2型糖尿病患者的抗氧化和抗炎生物标志物：一项观察性研究

目的：糖尿病是一种以高血糖为特征的慢性代谢疾病。作为2型糖尿病（T2DM）的主要治疗药物，二甲双胍在新诊断患者的抗氧化和抗炎生物标志物方面显示出积极的作用。方法：前瞻性观察性研究。采集了三次血液样本来分析生物标志物。该研究涉及新诊断的T2DM患者，他们提供书面知情同意书。评估包括血浆脂质过氧化、超氧化物歧化酶（SOD）、过氧化氢酶和丙二醛（MDA）水平。此外，测量白细胞介素-6 （IL-6）来评估炎症。结果：随访6个月，HbA1c水平明显下降。分析显示，每次就诊时SOD水平均有所降低，第一次和第二次随访差异有统计学意义（p=0.03028）。MDA水平在每次就诊时也有所下降，在第一次和第二次随访中有统计学上的显著差异(结论：二甲双胍减少2型糖尿病患者的氧化应激和炎症，有助于保护细胞和组织。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Basic and Clinical Physiology and Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.